Biotechnology
Cancer Diagnostics Market

Cancer Diagnostics Market Size, Share, Trends and Growth Forecasts, 2025-2032

Cancer Diagnostics Market by Diagnostic Test (Biomarker Test, Imaging Technology, Endoscopy, Others), by Application (Breast Cancer, Lung Cancer, Others), by End-use (Hospitals, Diagnostic Laboratories, Cancer Research Institutes), and Regional Analysis for 2025-2032

ID: PMRREP35187

April 2025

180 Pages

Author : Pravin Rewale

Healthcare

Category-wise Insights

Diagnostic Test Insights

Biopsy is the leading diagnostic test category in the cancer diagnostics market and is projected to hold 35.3% market share in 2025. This dominance is attributed to its high accuracy and the increasing prevalence of cancer globally. Advancements in minimally invasive biopsy techniques, such as liquid and image-guided, perform diagnostic precision while reducing patient discomfort. Governments and healthcare organizations are investing heavily in cancer screening programs further strengthens the role of biopsy. With continued innovation and integration of AI-driven pathology, biopsy is set to remain the cornerstone of cancer diagnostics, ensuring early detection and improved patient outcomes.

Application Insights

The increasing prevalence of smoking continues to be a significant factor fueling the growth of the lung cancer segment. According to the World Health Organization (WHO), tobacco use is responsible for nearly 85% of all lung cancer cases globally. Despite awareness campaigns, smoking rates remain high in several regions, particularly in developing countries, where the adoption of tobacco products is rising.

Additionally, clinical research affirms that a significant correlation exists between smoking and lung cancer. The World Health Organization (WHO) states that smokers face a higher likelihood of developing lung cancer than non-smokers. Additionally, the risk increases with both the quantity of cigarettes consumed daily and smoking frequency. Moreover, governments and healthcare organizations invest in initiatives to enhance diagnostic accessibility further propelling the demand for diagnostic lung cancer solutions.

End-User Insights

Hospitals continue to dominate largely due to the rising number of patients needing comprehensive diagnostic services and the increasing incorporation of advanced imaging technologies. The widespread adoption of in vitro diagnostics (IVD), along with imaging techniques, has played a significant role in enabling earlier and more accurate detection of various cancers, thereby enhancing clinical outcomes.

Diagnostic laboratories are witnessing growing demand, particularly in the consumables segment. Items such as antibodies, probes, and test kits are experiencing increased utilization, driven by the need for reliable, fast, and precise diagnostic tools. This segment commands a major portion of the market due to its efficiency in processing large sample volumes and supporting a wide range of cancer tests.

Cancer research institutes are placing a strong focus on emerging diagnostic approaches such as liquid biopsies and genomic profiling. These technologies provide critical molecular-level data to support the advancement of personalized medicine. The segment is expected to grow robust, aligning with the broader shift toward targeted therapies and individualized treatment plans. Additionally, ambulatory surgical centres embrace the point-of-care testing to improve diagnostic speed and decision-making. The development of compact, portable diagnostic equipment has facilitated quicker results and broader access, particularly in outpatient settings.

cancer diagnostics market insights and key trends

Get Your CustomizationGet Your Customization

Regional Insights and Trends

North America Cancer Diagnostics Market Trends

North America leads the global market, with a 42.3% share in 2025, driven by the advanced healthcare infrastructure, rising cancer cases, increased research funding, and an early adoption of innovative diagnostic technologies. The rise in the U.S. cancer cases and smoking-related fatalities in 2024 drives the need for advanced diagnostics. Innovations such as liquid biopsy and AI imaging enhance early detection. Increased healthcare spending and biotech collaborations further solidify North America’s advancement in cancer diagnostics.

Europe Cancer Diagnostics Market Trends

Europe is poised to experience a significant growth, driven by advancements in biotechnology and increased investments in genomic sequencing, particularly in the U.K. and Germany. The U.K. cancer diagnostics market is expected to grow due to the rising collaborations among key players, increased adoption of biomarker tests, and government initiatives supporting early detection. Advancements in genomic sequencing and innovative product launches, such as Invitae’s LiquidPlex Dx further drive market expansion across the country.

Asia Pacific Cancer Diagnostics Market Trends

Asia Pacific is expected to witness a robust growth driven by increasing healthcare reforms, urbanization, and economic expansion. Established players are expanding their regional footprint, further boosting market growth.

China’s cancer diagnostics market is projected to grow significantly due to the rise in cancer cases and advancements in early detection methods. According to the National Cancer Center China (NCCC), around 3.24 million new cases and 1.69 million deaths from cancer were reported in China in 2024. Companies are leveraging partnerships to expand multi-cancer early detection (MCED) test accessibility.

India is emerging as a key player in South Asia with an increasing focus on innovative technologies and early detection. According to the Indian Council of Medical Research (ICMR), India will witness over 1.57 million new cancer cases annually by 2025, a 12% increase from 2020. The demand for affordable and accessible diagnostic solutions drive investments in AI-based imaging, liquid biopsy, and biomarker testing.

MEA Cancer Diagnostics Market Trends

The Middle East and Africa presents significant growth opportunities. For underdeveloped African countries, lack of clinical access and infrastructure results in the lack of organized cancer screening programs. Companies such as Guardant Health, Pathcare, and others are actively enhancing cancer diagnostics in the MEA through technological advancements, strategic partnerships, and tailored programs aim to improve early detection and treatment outcome for cancer patients.

Competitive Landscape

The global cancer diagnostics market is highly competitive. Innovation, strategic alliances, and cutting-edge technologies are the strategies adopted by leading cancer diagnostics companies to improve early cancer detection. While Agilus Diagnostics has introduced sophisticated genome testing for quicker results, companies such as Bio-Rad Laboratories and Quidel Corporation are diversifying their molecular diagnostics offerings. To increase accuracy, businesses are also spending money on biomarker-based assays, liquid biopsy innovations, and AI-driven diagnostic tools. Their market presence is strengthened through partnerships with healthcare providers and research institutions.

Key Industry Developments:

In January 2025, Agilus Diagnostics introduced an advanced genome test designed to enhance the speed of cancer detection.
In February 2023, the World Health Organization (WHO) unveiled the Global Breast Cancer Initiative Framework, outlining a strategy to save 2.5 million lives from breast cancer by 2040.

Request Free sampleRequest Free sample

Companies Covered in Cancer Diagnostics Market

F. Hoffmann-La Roche Ltd
Thermo Fisher Scientific Inc.
Abbott Laboratories
Illumina Inc.
bioMérieux SA
Qiagen
Siemens Healthineers
GE Healthcare
Hologic Inc.
Koninklijke Philips N.V. (Philips)
Agilent Technologies Inc.
Becton, Dickinson and Company (BD)
Myriad Genetics Inc.
AstraZeneca
Regeneron
Novartis
Bio-Rad Laboratories
Cancer Diagnostics Inc.
Quidel Corporation
Others

Frequently Asked Questions

The global market is estimated to increase from US$137.8 billion in 2025 to US$222.7 billion in 2032.

The increasing demand for advanced diagnostic technologies and early screening programs drives the global market.

The market is projected to record a CAGR of 7.1% during the forecast period from 2025 to 2032.

Abbott Laboratories, Agilent Technologies Inc., Becton, Dickinson and Company (BD), bioMérieux SA, F. Hoffmann-La Roche Ltd, and Others.

Opportunities include AI-driven diagnostics, liquid biopsy advancements, biomarker-based testing, early screening programs, and global market expansion initiatives.

Top-Down Market Sizing	Bottom-Up Market Sizing
Universe Definition: Total global/regional market identification	Unit Economics: Average transaction values, purchase frequencies, customer lifecycle
Segmentation Filters: Geographic, demographic, and behavioral constraints	Customer Segmentation: Detailed buyer persona development and sizing
Market Share Analysis: Competitive landscape assessment and share allocation	Penetration Analysis: Market penetration rates by segment and geography
Growth Rate Application: Historical trends and forward-looking growth assumptions	Scaling Methodology: Extrapolation techniques with confidence intervals

Interested in this report?

Request customization, ask for expert consulting, access a sample report, or simply express your interest—our team will assist you with the right insights and solutions.

Request Custom VersionRequest Custom Version

Clients

Media Citation

Get In Touch

Loading page data

Please wait a moment

Executive Summary
1. Global Cancer Diagnostics Market Snapshot, 2025 and 2032
2. Market Opportunity Assessment, 2025 - 2032, US$ Bn
3. Key Market Trends
4. Future Market Projections
5. Premium Market Insights
6. Industry Developments and Key Market Events
7. PMR Analysis and Recommendations
Market Overview
1. Market Scope and Definition
2. Market Dynamics
  1. Drivers
  2. Restraints
  3. Opportunity
  4. Challenges
  5. Key Trends
3. COVID-19 Impact Analysis
4. Forecast Factors - Relevance and Impact
Value Added Insights
1. Value Chain Analysis
2. Diagnostic Test Adoption / Usage Analysis
3. Prevalence & Incidence of Cancer
4. Government Initiatives & Funding in Cancer Diagnostics
5. Key Market Players
6. Regulatory Landscape
7. PESTLE Analysis
8. Porter’s Five Force Analysis
9. Consumer Behavior Analysis
Global Cancer Diagnostics Market Outlook
1. Key Highlights
  1. Market Size (US$ Bn) and Y-o-Y Growth
  2. Absolute $ Opportunity
2. Market Size (US$ Bn) Analysis and Forecast
  1. Historical Market Size (US$ Bn) Analysis, 2019-2023
  2. Current Market Size (US$ Bn) Analysis and Forecast, 2024-2032
3. Global Cancer Diagnostics Market Outlook Diagnostic Test
  1. Historical Market Size (US$ Bn) Analysis, By Diagnostic Test, 2019-2023
  2. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2024-2032
    1. Biomarker Test
      1. Prostate-Specific Antigen (PSA)
      2. Circulating Tumor Cells (CTC)
      3. Alpha-Fetoprotein (AFP)
      4. Cancer Antigen 125 (CA-125)
      5. HER2
      6. Other
    2. Imaging Technology
      1. Magnetic Resonance Imaging (MRI)
      2. Computed Tomography (CT)
      3. Positron Emission Tomography (PET)
      4. Mammography
      5. Others
    3. Endoscopy
    4. Colonoscopy
    5. Biopsy
    6. Others
  3. Market Attractiveness Analysis: Diagnostic Test
4. Global Cancer Diagnostics Market Outlook Form
  1. Historical Market Size (US$ Bn) Analysis, By Form, 2019-2023
  2. Current Market Size (US$ Bn) Analysis and Forecast, By Form, 2024-2032
    1. Isolates
    2. Concentrates
    3. Hydrolysates
  3. Market Attractiveness Analysis: Form
5. Global Cancer Diagnostics Market Outlook Application
  1. Historical Market Size (US$ Bn) Analysis, By Application, 2019-2023
  2. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2032
    1. Lung Cancer
    2. Breast Cancer
    3. Prostate Cancer
    4. Colorectal Cancer
    5. Melanoma Cancer
    6. Blood Cancer
    7. Ovarian Cancer
    8. Other
  3. Market Attractiveness Analysis: Application
6. Global Cancer Diagnostics Market Outlook End-use
  1. Historical Market Size (US$ Bn) Analysis, By End-use, 2019-2023
  2. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2024-2032
    1. Hospitals
    2. Diagnostic Laboratories
    3. Cancer Research Institutes
    4. Ambulatory Surgical Centers
  3. Market Attractiveness Analysis: End-use
Global Cancer Diagnostics Market Outlook Region
1. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2023
2. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024-2032
  1. North America
  2. Latin America
  3. Europe
  4. East Asia
  5. South Asia and Oceania
  6. Middle East & Africa
3. Market Attractiveness Analysis: Region
North America Cancer Diagnostics Market Outlook
1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  1. By Country
  2. By Diagnostic Test
  3. By Application
  4. By End-use
2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
  1. U.S.
  2. Canada
3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2024-2032
  1. Biomarker Test
    1. Prostate-Specific Antigen (PSA)
    2. Circulating Tumor Cells (CTC)
    3. Alpha-Fetoprotein (AFP)
    4. Cancer Antigen 125 (CA-125)
    5. HER2
    6. Other
  2. Imaging Technology
    1. Magnetic Resonance Imaging (MRI)
    2. Computed Tomography (CT)
    3. Positron Emission Tomography (PET)
    4. Mammography
    5. Others
  3. Endoscopy
  4. Colonoscopy
  5. Biopsy
  6. Others
4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2032
  1. Lung Cancer
  2. Breast Cancer
  3. Prostate Cancer
  4. Colorectal Cancer
  5. Melanoma Cancer
  6. Blood Cancer
  7. Ovarian Cancer
  8. Other
5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2024-2032
  1. Hospitals
  2. Diagnostic Laboratories
  3. Cancer Research Institutes
  4. Ambulatory Surgical Centers
6. Market Attractiveness Analysis
Europe Cancer Diagnostics Market Outlook
1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  1. By Country
  2. By Diagnostic Test
  3. By Form
  4. By Application
  5. By End-use
2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
  1. Germany
  2. France
  3. U.K.
  4. Italy
  5. Spain
  6. Russia
  7. Rest of Europe
3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2024-2032
  1. Biomarker Test
    1. Prostate-Specific Antigen (PSA)
    2. Circulating Tumor Cells (CTC)
    3. Alpha-Fetoprotein (AFP)
    4. Cancer Antigen 125 (CA-125)
    5. HER2
    6. Other
  2. Imaging Technology
    1. Magnetic Resonance Imaging (MRI)
    2. Computed Tomography (CT)
    3. Positron Emission Tomography (PET)
    4. Mammography
    5. Others
  3. Endoscopy
  4. Colonoscopy
  5. Biopsy
  6. Others
4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2032
  1. Lung Cancer
  2. Breast Cancer
  3. Prostate Cancer
  4. Colorectal Cancer
  5. Melanoma Cancer
  6. Blood Cancer
  7. Ovarian Cancer
  8. Other
5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2024-2032
  1. Hospitals
  2. Diagnostic Laboratories
  3. Cancer Research Institutes
  4. Ambulatory Surgical Centers
6. Market Attractiveness Analysis
East Asia Cancer Diagnostics Market Outlook
1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  1. By Country
  2. By Diagnostic Test
  3. By Application
  4. By End-use
2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
  1. China
  2. Japan
  3. South Korea
3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2024-2032
  1. Biomarker Test
    1. Prostate-Specific Antigen (PSA)
    2. Circulating Tumor Cells (CTC)
    3. Alpha-Fetoprotein (AFP)
    4. Cancer Antigen 125 (CA-125)
    5. HER2
    6. Other
  2. Imaging Technology
    1. Magnetic Resonance Imaging (MRI)
    2. Computed Tomography (CT)
    3. Positron Emission Tomography (PET)
    4. Mammography
    5. Others
  3. Endoscopy
  4. Colonoscopy
  5. Biopsy
  6. Others
4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2032
  1. Lung Cancer
  2. Breast Cancer
  3. Prostate Cancer
  4. Colorectal Cancer
  5. Melanoma Cancer
  6. Blood Cancer
  7. Ovarian Cancer
  8. Other
5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2024-2032
  1. Hospitals
  2. Diagnostic Laboratories
  3. Cancer Research Institutes
  4. Ambulatory Surgical Centers
6. Market Attractiveness Analysis
South Asia & Oceania Cancer Diagnostics Market Outlook
1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  1. By Country
  2. By Diagnostic Test
  3. By Application
  4. By End-use
2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
  1. India
  2. Indonesia
  3. Thailand
  4. Singapore
  5. ANZ
  6. Rest of South Asia & Oceania
3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2024-2032
  1. Biomarker Test
    1. Prostate-Specific Antigen (PSA)
    2. Circulating Tumor Cells (CTC)
    3. Alpha-Fetoprotein (AFP)
    4. Cancer Antigen 125 (CA-125)
    5. HER2
    6. Other
  2. Imaging Technology
    1. Magnetic Resonance Imaging (MRI)
    2. Computed Tomography (CT)
    3. Positron Emission Tomography (PET)
    4. Mammography
    5. Others
  3. Endoscopy
  4. Colonoscopy
  5. Biopsy
  6. Others
4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2032
  1. Lung Cancer
  2. Breast Cancer
  3. Prostate Cancer
  4. Colorectal Cancer
  5. Melanoma Cancer
  6. Blood Cancer
  7. Ovarian Cancer
  8. Other
5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2024-2032
  1. Hospitals
  2. Diagnostic Laboratories
  3. Cancer Research Institutes
  4. Ambulatory Surgical Centers
6. Market Attractiveness Analysis
Latin America Cancer Diagnostics Market Outlook
1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  1. By Country
  2. By Diagnostic Test
  3. By Application
  4. By End-use
2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
  1. Brazil
  2. Mexico
  3. Rest of Latin America
3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2024-2032
  1. Biomarker Test
    1. Prostate-Specific Antigen (PSA)
    2. Circulating Tumor Cells (CTC)
    3. Alpha-Fetoprotein (AFP)
    4. Cancer Antigen 125 (CA-125)
    5. HER2
    6. Other
  2. Imaging Technology
    1. Magnetic Resonance Imaging (MRI)
    2. Computed Tomography (CT)
    3. Positron Emission Tomography (PET)
    4. Mammography
    5. Others
  3. Endoscopy
  4. Colonoscopy
  5. Biopsy
  6. Others
4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2032
  1. Lung Cancer
  2. Breast Cancer
  3. Prostate Cancer
  4. Colorectal Cancer
  5. Melanoma Cancer
  6. Blood Cancer
  7. Ovarian Cancer
  8. Other
5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2024-2032
  1. Hospitals
  2. Diagnostic Laboratories
  3. Cancer Research Institutes
  4. Ambulatory Surgical Centers
6. Market Attractiveness Analysis
Middle East & Africa Cancer Diagnostics Market Outlook
1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  1. By Country
  2. By Diagnostic Test
  3. By Application
  4. By End-use
2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
  1. GCC Countries
  2. Egypt
  3. South Africa
  4. Northern Africa
  5. Rest of Middle East & Africa
3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2024-2032
  1. Biomarker Test
    1. Prostate-Specific Antigen (PSA)
    2. Circulating Tumor Cells (CTC)
    3. Alpha-Fetoprotein (AFP)
    4. Cancer Antigen 125 (CA-125)
    5. HER2
    6. Other
  2. Imaging Technology
    1. Magnetic Resonance Imaging (MRI)
    2. Computed Tomography (CT)
    3. Positron Emission Tomography (PET)
    4. Mammography
    5. Others
  3. Endoscopy
  4. Colonoscopy
  5. Biopsy
  6. Others
4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2032
  1. Lung Cancer
  2. Breast Cancer
  3. Prostate Cancer
  4. Colorectal Cancer
  5. Melanoma Cancer
  6. Blood Cancer
  7. Ovarian Cancer
  8. Other
5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2024-2032
  1. Hospitals
  2. Diagnostic Laboratories
  3. Cancer Research Institutes
  4. Ambulatory Surgical Centers
6. Market Attractiveness Analysis
Competition Landscape
1. Market Share Analysis, 2024
2. Market Structure
  1. Competition Intensity Mapping by Market
  2. Competition Dashboard
3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  1. F. Hoffmann-La Roche Ltd
    1. Overview
    2. Segments and Sources
    3. Key Financials
    4. Market Developments
    5. Market Strategy
  2. Thermo Fisher Scientific Inc.
  3. Abbott Laboratories
  4. Illumina Inc.
  5. bioMérieux SA
  6. Qiagen
  7. Siemens Healthineers
  8. GE Healthcare
  9. Hologic Inc.
  10. Agilent Technologies Inc.
  11. Becton, Dickinson and Company (BD)
  12. Myriad Genetics Inc.
  13. AstraZeneca
  14. Regeneron
  15. Novartis
  16. BIO-RAD LABORATORIES
  17. CANCER DIAGNOSTICS INC.
  18. QUIDEL CORPORATION
  19. Koninklijke Philips N.V. (Philips)
  20. Others
Appendix
1. Research Methodology
2. Research Assumptions
3. Acronyms and Abbreviations

Global Market Attribute	Key Insights
Cancer Diagnostics Market Size (2025E)	US$ 137.8 Bn
Market Value Forecast (2032F)	US$ 222.7 Bn
Projected Growth (CAGR 2025 to 2032)	7.1%
Historical Market Growth (CAGR 2019 to 2024)	6.5%

Report Attribute	Details
Historical Data/Actuals	2019 - 2024
Forecast Period	2025 - 2032
Market Analysis Units	Value: US$ Bn, Volume: As applicable
Geographical Coverage	North America Europe East Asia South Asia and Oceania Middle East and Africa Latin America
Segmental Coverage	Diagnostic Test Application End-use Region
Competitive Analysis	F. Hoffmann-La Roche Ltd Thermo Fisher Scientific Inc. Abbott Laboratories Illumina Inc. bioMérieux SA Qiagen Siemens Healthineers GE Healthcare Hologic Inc. Koninklijke Philips N.V. (Philips) Agilent Technologies Inc. Becton, Dickinson and Company (BD) Myriad Genetics Inc. AstraZeneca Regeneron Novartis Bio-Rad Laboratories Cancer Diagnostics Inc. Quidel Corporation Others
Report Highlights	Market Forecast and Trends Competitive Intelligence & Share Analysis Growth Factors and Challenges Strategic Growth Initiatives Future Opportunities and Revenue Pockets Industry Market Analysis Tools
Customization and Pricing	Available upon request

Global Market Attribute	Key Insights
Cancer Diagnostics Market Size (2025E)	US$ 137.8 Bn
Market Value Forecast (2032F)	US$ 222.7 Bn
Projected Growth (CAGR 2025 to 2032)	7.1%
Historical Market Growth (CAGR 2019 to 2024)	6.5%

Report Attribute	Details
Historical Data/Actuals	2019 - 2024
Forecast Period	2025 - 2032
Market Analysis Units	Value: US$ Bn, Volume: As applicable
Geographical Coverage	North America Europe East Asia South Asia and Oceania Middle East and Africa Latin America
Segmental Coverage	Diagnostic Test Application End-use Region
Competitive Analysis	F. Hoffmann-La Roche Ltd Thermo Fisher Scientific Inc. Abbott Laboratories Illumina Inc. bioMérieux SA Qiagen Siemens Healthineers GE Healthcare Hologic Inc. Koninklijke Philips N.V. (Philips) Agilent Technologies Inc. Becton, Dickinson and Company (BD) Myriad Genetics Inc. AstraZeneca Regeneron Novartis Bio-Rad Laboratories Cancer Diagnostics Inc. Quidel Corporation Others
Report Highlights	Market Forecast and Trends Competitive Intelligence & Share Analysis Growth Factors and Challenges Strategic Growth Initiatives Future Opportunities and Revenue Pockets Industry Market Analysis Tools
Customization and Pricing	Available upon request

Cancer Diagnostics Market Size, Share, Trends and Growth Forecasts, 2025-2032

Cancer Diagnostics Market by Diagnostic Test (Biomarker Test, Imaging Technology, Endoscopy, Others), by Application (Breast Cancer, Lung Cancer, Others), by End-use (Hospitals, Diagnostic Laboratories, Cancer Research Institutes), and Regional Analysis for 2025-2032